



EXPRESS MAIL NUMBER
EV33399645US

#10
Call 1103

RECEIVED
JUN 06 2003
TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT Address to: Commissioner for Patents Arlington, VA	Attorney Docket	Ucal-105CIP2
	First Named Inventor	Robert V. Farese, Jr.
	Application Number	10/040,315
	Filing Date	October 29, 2001
	Group Art Unit	1632
	Examiner Name	V. Bertoglio
	Title: DIACYGLYCEROL O-ACYLTRANSFERASE	

Sir:

This is in response to the Restriction Requirement dated April 22, 2003. The Examiner therein required election of one of the following groups of claims:

- 1-5, 10-13, 15-16, 20-21, 23
- Group I: Claims 1-5, 8, 10-13, 15, 16, 20, 21 and 23, drawn to a non-human animal characterized by having a transgene altering the naturally occurring, endogenous DGAT gene and a method of using said animal; *method of testing in vivo*
- Group II: Claims 1-8, 10-16, 20, 21 and 22, drawn to a non-human animal characterized by having a transgene altering the naturally occurring, endogenous DGAT gene and further comprising a transgene comprising an exogenous DGAT coding sequence and a method of using said animal;
- Group III: Claims 1, 3-5, 8 and 9, drawn to non-human animal characterized by having an extra, transgene-encoded endogenous DGAT gene;
- Group IV: *in vitro* Claims 15-19, drawn to an in vitro assay for screening candidate agents for modulatory activity of DGAT activity; *in vitro*
- Group V: Claims 15-18 and 20-23, drawn to an in vivo assay for screening candidate agents for modulatory activity of DGAT activity; *in vivo*
- Group VI: Claims 24-26, 28 and 29, drawn to an in vitro assay for screening candidate agents for modulatory activity of DGAT expression; and
- Group VII: Claims 24-25 and 27-29, drawn to an in vivo assay for screening candidate agents for modulatory activity of DGAT expression.